ACM
NBIX icon

Atika Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Atika Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-70,000
Closed -$6.17M – 85
2019
Q1 		$6.17M Hold
70,000
– – 1.25% 34
2018
Q4 		$5M Buy
+70,000
New +$6.71M 1.47% 25

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's NBIX Position: Q1 2025 in Review

Atika Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 48,000 shares — an estimated $6.55M sold.

Atika Capital Management first reported a position in NBIX in Q4 2014 and held it in 13 quarters. The position peaked at $8M in Q1 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Atika Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Atika Capital Management sold 48,000 Neurocrine Biosciences shares in Q1 2025, an estimated $6.55M.
  • Atika Capital Management first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 13 quarters.
  • Atika Capital Management's Neurocrine Biosciences position peaked at $8M in Q1 2024.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Atika Capital Management's 13F filing for Q1 2025, filed 14 May 2025.